Treats onychomycosis of the toenail or fingernail due to dermatophytes (tinea unguium). ANDA 77714, held by Breckenridge Pharmaceutical. Terbinafine Hydrochloride.
As of Nov 22, 2026, ANDA 77714 (Terbinafine Hydrochloride), held by Breckenridge Pharmaceutical, was first approved by FDA on Jun 4, 2010, with 4 approved supplements and 0 published complete response letters.
1. INDICATIONS AND USAGE Terbinafine tablets are indicated for the treatment of onychomycosis of the toenail or fingernail due to dermatophytes (tinea unguium). Prior to initiating treatment, appropriate nail specimens for laboratory testing [potassium hydroxide (KOH) preparation, fungal culture, or nail biopsy] should be obtained to confirm the diagnosis of onychomycosis. Terbinafine tablets are an allylamine antifungal
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 4, 2010 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Terbinafine HydrochlorideEQ 250MG BASE · tablet;oral | Terbinafine Hydrochloride | Discontinued |
| Dec 20, 2024 | Supplement 3Labeling · Standard review | Approved | None posted |
| Dec 20, 2024 | Supplement 7Labeling · Standard review | Approved | None posted |
| Dec 20, 2024 | Supplement 9Labeling · Standard review | Approved | None posted |
| Apr 10, 2012 | Supplement 1Labeling | Approved | None posted |
| Jun 4, 2010 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters